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Abstract
OBJECTIVE—Early follicular phase follicle stimulating hormone (FSH), a marker of ovarian
reserve, has been used to predict time to menopause. A mother’s age at menopause is related to
daughter’s age at menopause, possibly due to genetic factors. This study sought to determine the
relationship between maternal age at menopause and early follicular phase FSH of premenopausal
daughters.
DESIGN—The Uterine Fibroid Study enrolled women randomly selected from a prepaid health
plan, collected questionnaire data, and obtained early follicular phase urine samples on a subset of
participants. For this secondary analysis, premenopausal women between the ages of 35 and 46
years, who provided a urine sample on cycle day 2,3,4, or 5 and their mother’s age at natural
menopause (N=182) were selected from the original cohort. Initially bivariate analysis and
subsequently regression modeling was conducted to assess the independent relationship between
maternal age at menopause and urinary creatinine-corrected FSH.
RESULTS—Unadjusted analyses and those adjusting for age (mean, 40.5 ±3.2 years), smoking
status (16 % current smokers), and body mass index (mean, 26.8 ±6.9 kg/m2) showed a significant
association between maternal age at menopause and daughter’s urinary FSH level (p<0.04).
Women whose mothers experienced earlier menopause had higher urinary FSH levels.
CONCLUSIONS—The significantly increased FSH values among women whose mothers
experienced early menopause is consistent with previously reported associations between mother’s
and daughter’s age of menopause. FSH, a marker of reserve of the ovary, is influenced by both
genetic and environmental factors. Future epidemiologic studies on FSH should collect
information on maternal age at menopause.
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Reproductive aging of women is the natural progression through stages of puberty, fertility,
subfertility, the menopause transition and finally menopause.1 Women progress through
these reproductive stages due to a decline in both the quantity and quality of ovarian oocytes
and follicles. In the aging ovary, fewer follicles results in reduced follicular production of
the hormone inhibin B, leading to diminished suppression of the anterior pituitary, increased
follicle stimulating hormone (FSH) production, and higher serum FSH levels during the
early follicular phase of the menstrual cycle. Accordingly, early follicular phase serum FSH
levels rise as the number of remaining oocytes declines.
Based on the hormonal changes observed with ovarian aging, serum FSH levels have been
used as an indirect marker of reproductive potential. FSH levels are predictive of fecundity
with fertility treatment.2 Levels appear to rise as a woman goes through the menopausal
transition from menstrual regularity to irregularity to amenorrhea.3 In addition, FSH values
appear to correlate with time to menopause in women between the ages of 40 and 49, and
extreme FSH levels (>20 IU/L) are predictive of menopause (positive predictive value:
73%).5 Urinary FSH is highly correlated with serum values (r=0.75–0.88) and acts similarly
as a marker of ovarian aging.6,7
Women may vary in age at menopause due to differences in the size of the oocyte pool at
birth or to differences in the rate of oocyte loss.8 Previous studies have shown that both
genetic and environmental factors determine the age at which women will enter menopause.
9,10 Maternal menopausal age appears to be a strong predictor of age at menopause.11–13
The mechanism by which a mother’s age at menopause determines the daughter’s age at
menopause is not known.
Assuming women destined to undergo early menopause will have a smaller oocyte pool,
early follicular phase FSH should be higher in this group of women compared to women
destined to go through menopause later. Based on this assumption, FSH values should be
higher in women whose mothers had an early menopausal age compared to women with
mothers with a later menopausal age. This study sought to test this hypothesis by
determining the relationship between maternal age at menopause and early follicular phase
FSH among late reproductive age women.
METHODS
This study is a secondary analysis of data from the National Institute of Environmental
Health Sciences Uterine Fibroids Study, which was designed to 1) measure prevalence of
fibroids by screening a representative group of women and 2) identify risk factors for the
condition. A detailed description of the study design has been published previously.14 In
summary, 35–49 year old women were selected randomly from computerized membership
records of a prepaid health plan in Washington, DC. Health plan members were eligible if
they could be contacted by telephone, their records confirmed, and they spoke English.
Demographic information, reproductive status, medical history, and social history were
obtained from participants (N= 1430) using a combination of a self-administered
questionnaire and telephone interview. The take-home, self-administered questionnaire
included questions about the cause of the mother’s menopause (natural or surgical) and age
it occurred, allowing respondents to possibly query their mothers. Of the 1237 women that
completed the questionnaire 62% provided information about their mother’s type and age of
menopause.
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The first 638 of the 1243 premenopausal participants were asked to collect first morning
urine samples on the second and third days of their menstrual cycles. The samples were
initially stored in the subject’s refrigerator and then shipped within a day via overnight
courier in a cold-storage pack to the study management site in North Carolina where equal
aliquots from each day were pooled. The premenopausal subjects who did not collect
menstrually-timed urine were asked to bring a first morning urine specimen, collected the
day of their study clinic visit. Those participants that presented to the clinic without urine
were asked to provide a spot urine sample, and their menstrual cycle day was recorded.
Seven percent glycerol was added to all samples and the samples stored at −80C to prevent
loss of hormone activity.15 In all, 927 women provided urine, but many of these were not
early follicular phase specimens. Serum FSH values have been shown to be consistent
between menstrual cycle days 2–5,16–17 so we limited analysis to specimens from those
days. There were a total of 467 women with urine samples from menstrual days 2–5; 383 of
them were 46 years of age or less. Of the 383 women, 344 (90%) provided 2day pooled
first-morning urine samples, 30 (8%) provided single first morning urine samples, and 8
(2%) provided single spot urine samples.
Urinary FSH was assayed in duplicate using a modified commercial non-competitive, two-
site time-resolved immunofluorometric assay.18 Creatinine was measured
spectrophotometrically19. Endocrine values were divided by creatinine concentrations to
adjust for urine dilution.20 Within-and between-assay percent coefficients of variation were
3.1% and 1.1% for FSH and 2.2% and 4.2% for creatinine.
We limited analysis to participants who were age 46 or younger for two reasons. First, very
few women in our sample had experienced natural menopause by age 46, so selection of
premenopausal women would not bias our analysis. Second, previous studies have shown
that FSH and age are very highly associated for older women.5,21 By restricting our
analysis, any relationship between mother’s age at menopause and FSH would not be as
obscured by the strong association between FSH and age.
Mother’s age at menopause was grouped into three categories: less than 46 years of age, 46
to 49 years, and 50 years or older. If the daughter reported that her mother had surgical
menopause before age 50, her age at menopause could not be categorized, but if the
daughter reported her mother had surgical menopause and surgery occurred after age 50
(N=17), mother’s age at menopause was grouped in the 50 and over category. Of the 383
women with FSH data, 239 (62%) provided information about their mother’s type and age
of menopause. The 57 subjects (24%), who reported that their mother underwent surgical
menopause before age 50, were excluded, leaving 182 for analysis of the relationship
between maternal age at menopause and daughter’s urinary FSH. Data Analysis
Analysis of variance and linear regression were used to determine the unadjusted
relationship between FSH and each of the following variables: maternal age at menopause,
age, race, education, body mass index, parity by age 35, and smoking status. Subsequently a
model was created to assess the independent relationship between maternal age at
menopause and urinary FSH (after log transformation) adjusting for potential confounders.
Independent variables were considered to be confounders if they changed the measure of
association between maternal age at menopause and urinary FSH by more than 10%.
Categorical variables (smoking status, race, and education) were modeled using indicator
variables. Parity by age 35 was coded as a ranked categorical variable. Age, BMI, and cycle
day were modeled as continuous variables. The final model included age, current smoking
status (yes/no), and BMI as covariates. Urinary FSH values were estimated for each
independent variable (categorized for presentation purposes) using analysis of covariance
with covariates set to the mean. Significance of the relationship between each independent
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variable and urinary FSH was determined using a t-test for continuous or dichotomous
variables, F-test for categorical variables, and a test of trend t-test for ranked variables. The
robustness of the maternal age at menopause effect was evaluated by substituting the mean
for each category (mean for those with natural menopause, 52.7 years, used for the maternal
age at menopause category of 50+).
RESULTS
We compared daughters with data on mother’s age at menopause to those without data.
Compared to daughters without, those with data on mother’s age at menopause were lighter
weight (mean BMI=26.8 ±6.9 kg/m2 versus 29.1 ±8.1, p=0.003), better educated (p=0.01),
less likely to smoke (16% versus 24%, p=0.05), more likely to be white (45% versus 32%,
p=0.05) but similar in age (40.9 ±3.0 years versus 40.5± 3.2, p=0.2). Average FSH of the
daughters for whom we could not categorize mother’s age at menopause (N=201) was
similar to that of the daughters for whom we could categorize mother’s age at menopause
(N=182) (11.2 versus 11.1 mIU/mg creatinine, respectively, p=0.9).
Early follicular phase FSH values ranged from 0.58–69.3 mIU/mg creatinine (mean 11.1,,
median 9.3). Unadjusted analyses showed that of the covariates, only smoking status was a
statistically significant predictor of early follicular phase urinary FSH. Current smokers had
higher early follicular phase urinary FSH values than current non-smokers (14.5 ±12.5mIU/
mg creatinine versus 10.5 ±6.8, p=0.03). BMI was next most important but not statistically
significant (p=0.06). As BMI increased, FSH values decreased. Values did not differ by age,
day of collection (day 2,3,4, or 5) (P=0.7), race, education level, or parity by age 35.
Table 1 shows the relationship between maternal age at menopause and participant urinary
FSH level. Early maternal menopause was significantly associated with higher urinary FSH
levels in their daughters (P< 0.04 for both unadjusted and age-adjusted analyses). The
relationship was somewhat stronger with full covariate adjustment (P = 0.01). Substituting
the categorical mean maternal age at menopause for each individual maternal age at
menopause in the model confirmed the significance of the relationship (P=0.01).
In the fully-adjusted model, smoking and BMI were the only covariates significantly
associated with FSH levels. Current smokers had significantly higher urinary FSH values
compared to current non-smokers (estimated urinary FSH: 12.0 versus 8.6 mIU/mg
creatinine respectively, P < 0.02), and obese women had lower urinary FSH values
compared to women in the three lower categories of BMI (estimated urinary FSH: 7.1 versus
9.3, 9.6, and 11.4 mIU/mg creatinine, P=0.01). We reexamined former smokers and number
of cigarettes in the full model and found that current smokers had higher urinary FSH levels
than both never-smokers (P=0.04) and former smokers (P=0.03). There was no significant
difference between the never and former smokers (P=0.6). Urinary FSH did not differ by
number of cigarettes smoked by current smokers (P=0.5).
DISCUSSION
In this study we found that mother’s age at menopause may help predict the daughter’s
urinary FSH value. A subject’s smoking status and BMI were also important, with smoking
associated with higher FSH and excess weight associated with lower FSH. These findings
support the hypothesis that both genetic and environmental factors contribute to FSH level
and presumably to ovarian aging for which FSH is a biomarker.
Previous studies have shown that a woman’s age at menopause is related to her mother’s age
at menopause.11–13 This relationship may be due to genetics or common behaviors, such as
tobacco use, dietary intake, and physical activities. A genetic hypothesis is supported by
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twin studies, which reveal a heritability for age at menopause of 63%.22 Pedigree analyses
have revealed a potential dominant pattern of inheritance of early menopause (menopause
between ages 40 and 45) and premature ovarian failure (menopause prior to age 40) through
maternal or paternal relatives.23,24 One potential familial cause of early menopause and
premature ovarian failure are alterations in the FMR1 gene. Mutation of the FMR1 gene,
due to expansion of the CGG repeat to over 200 copies, leads to Fragile X syndrome.
Trinucleotide repeats of 50–200 in the FMR1 gene is associated with premature ovarian
failure.25 The length of the trinucleotide repeat has been correlated with age at menopause.
26 Women with longer repeat sequences had earlier onset of menopause and women with
shorter sequences had later onset.
Similarities in mother and daughter ages at menopause may also be attributed to common
habits such as smoking, education level, and diet/exercise resulting in similar BMI.13
However, when we controlled for these factors the effect of maternal age of menopause on
FSH was not reduced, suggesting that the impact of maternal timing of menopause could be
largely due to genetic phenomena rather than shared environment.
Environmental factors that predict age of menopause also appear to be associated with
elevated FSH levels. Current smoking and unilateral oophorectomy both appear to result in
earlier onset of menopause27–29 and higher premenopausal FSH levels2,5,30,31 while
moderate alcohol use and increases in body mass index have been associated with delayed
onset of11,12,32 menopause.BMI has also been associated with lower premenopausal FSH
levels.3,21
Although their mechanisms may differ, these factors may ultimately be linked to variation in
the size or quality of the oocyte pool, presumably resulting in changes in serum FSH levels
and in timing of onset of menopause.
Our findings that mother’s age at menopause predicts daughter’s FSH levels suggests that
when FSH is used to monitor environmental impacts of potential reproductive toxicants on
ovarian physiology, data on mother’s age of menopause should be collected as a potential
confounder or to improve precision of estimates. Future studies of younger women may
determine whether the disparity in FSH between women with early and late maternal
menopausal ages is due to a difference in the size of the initial oocyte pool or due to a
difference in the rate of oocyte depletion.
In our study of women between 35 and 46 years of age, we did not detect a significant
relationship between urinary FSH and age. This finding may be due to several factors. First,
this could be a chance result of our selection criteria. Second, the age range in our analysis
was narrow. Third, we focused on younger women than have usually been described in the
literature. The association between age and FSH may not be as strong in this age range as in
older ages. NHANES III survey showed that for the majority of women FSH remains
relatively stable until age 45, when the values begin to rise.5
This study is limited by the fact that daughters provided the age at which their mothers went
through menopause. The validity of this form of data collection has not been tested and has
the potential for exposure misclassification due to preferential recall by the perimenopausal
subjects. Also, many mothers underwent hysterectomy prior to natural menopause and
before age 50. We were unable to include them in the analysis, thus limiting the power of
our study, increasing the probability that chance may explain the study findings. In addition,
not all women are able to provide information on their mother’s age at menopause (only
62% in our sample).
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Although, they did not have significant differences in mean urinary FSH values, women
who are able to provide information about their mother’s age at menopause do differ from
those that do not.. Postmenopausal women were not included in our study; however, we
limited the analysis to women age 46 and younger, an age group from which very few
women were excluded due to early natural menopause. The study is strengthened by the
collection and assessment of multiple covariates. The study may have benefited from
collection and adjustment for other conditions thought to impact on FSH such as ovarian
surgery.
CONCLUSIONS
Maternal age at menopause is a significant predictor of urinary FSH, a marker of ovarian
aging. Urinary FSH is an important independent predictor of ovarian aging independent of
age. FSH is influenced by genetic and environmental factors, such as tobacco use and body
mass index. Epidemiologic studies using FSH as a marker of reproductive toxicity should
consider collecting information on maternal age at menopause from study participants.
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Urinary FSH of Daughter, mIU/mg creatinine
Mean (SD) Age-adjusted mean (95% CI)a
Fully-adjusted mean (95%
CI)a.b
<46 y 25 13.4 (9.2) 11.0 (8.5–14.3) 11.7 (9.0–15.2)
46–49 y 23 12.5 (6.6) 10.8 (8.2–14.1) 10.9 (8.3–14.2)
≥50 y 134 10.5 (8.0) 8.5 (7.6–9.5) 8.4 (7.5–9.4)
P-valuec 0.037 0.038 0.01
FSH, follicle stimulating hormone* Linear regression test of trend.
a
Analysis does not include subjects, whose a After back-transformation from log FSH.
b
Adjusted for age, current smoking status (yes/no) and body mass index.
c
Linear regression test of trend.
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